MannKind (NASDAQ:MNKD – Get Free Report) and MeiraGTx (NASDAQ:MGTX – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, profitability and valuation.
Analyst Ratings
This is a breakdown of current ratings and price targets for MannKind and MeiraGTx, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MannKind | 2 | 1 | 6 | 0 | 2.44 |
| MeiraGTx | 1 | 0 | 5 | 2 | 3.00 |
MannKind presently has a consensus target price of $8.39, suggesting a potential upside of 106.72%. MeiraGTx has a consensus target price of $26.17, suggesting a potential upside of 88.38%. Given MannKind’s higher possible upside, analysts plainly believe MannKind is more favorable than MeiraGTx.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MannKind | $348.97 million | 3.74 | $5.86 million | ($0.13) | -31.23 |
| MeiraGTx | $81.39 million | 16.39 | -$114.20 million | $0.71 | 19.56 |
MannKind has higher revenue and earnings than MeiraGTx. MannKind is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
49.5% of MannKind shares are held by institutional investors. Comparatively, 67.5% of MeiraGTx shares are held by institutional investors. 2.6% of MannKind shares are held by insiders. Comparatively, 7.4% of MeiraGTx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Risk & Volatility
MannKind has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500. Comparatively, MeiraGTx has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500.
Profitability
This table compares MannKind and MeiraGTx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MannKind | -11.08% | -11.21% | -6.31% |
| MeiraGTx | 19.87% | 283.85% | 29.39% |
Summary
MeiraGTx beats MannKind on 11 of the 15 factors compared between the two stocks.
About MannKind
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
About MeiraGTx
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.
Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.
